Safety and pharmacokinetics of bimagrumab in healthy older and obese adults with body composition changes in the older cohort

The Importance of Resistance Exercise Training to Combat Neuromuscular Aging

(2019) Kaleen M. Lavin et al.   PHYSIOLOGY

Growth differentiation factor 11 (GDF11) has pronounced effects on skin biology

(2019) Jolanta Idkowiak-Baldys et al.   PLoS One

Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial

(2019) Michael G Hanna et al.   LANCET NEUROLOGY

Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle : update 2019

(2019) Stephan Haehling et al.   Journal of Cachexia Sarcopenia and Muscle

Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes

(2018) Tania Garito et al.   CLINICAL ENDOCRINOLOGY

Advanced body composition assessment: from body mass index to body composition profiling

(2018) Magnus Borga et al.   JOURNAL OF INVESTIGATIVE MEDICINE

Activin Type II Receptor Blockade for Treatment of Muscle Depletion in COPD: A Randomized Trial

(2018) Michael I Polkey et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

High-Intensity Resistance and Impact Training Improves Bone Mineral Density and Physical Function in Postmenopausal Women With Osteopenia and Osteoporosis: The LIFTMOR Randomized Controlled Trial

(2017) Steven L Watson et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof-of-Concept Study

(2017) Daniel Rooks et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy

(2017) Frederic Morvan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Effect of bimagrumab on thigh muscle volume and composition in men with casting-induced atrophy

(2017) Daniel S. Rooks et al.   Journal of Cachexia Sarcopenia and Muscle

Dose–Response Relationships of Resistance Training in Healthy Old Adults: A Systematic Review and Meta-Analysis

(2015) Ron Borde et al.   SPORTS MEDICINE

Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial

(2015) Clemens Becker et al.   Lancet Diabetes & Endocrinology

Treatment of sporadic inclusion body myositis with bimagrumab

(2014) A. A. Amato et al.   NEUROLOGY

An Antibody Blocking Activin Type II Receptors Induces Strong Skeletal Muscle Hypertrophy and Protects from Atrophy

(2013) E. Lach-Trifilieff et al.   MOLECULAR AND CELLULAR BIOLOGY

A single ascending-dose study of muscle regulator ace-031 in healthy volunteers

(2012) Kenneth M. Attie et al.   MUSCLE & NERVE

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

(2010) Ron J. Keizer et al.   CLINICAL PHARMACOKINETICS

Regulation of Muscle Mass by Follistatin and Activins

(2010) Se-Jin Lee et al.   MOLECULAR ENDOCRINOLOGY

Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size

(2009) Anne Ulrike Trendelenburg et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY